
Lincoln Pharmaceuticals (LINCOLN): Lincoln Pharma Share Price Falls 8.76% Today to Rs 508.70
Updated: 29 Oct 2026 • 12:42 pm
Posted by:

Lincoln Pharma Share Price is under pressure today, with Lincoln Pharmaceuticals (LINCOLN) trading at Rs 508.70 as of 29 October 2026 at 12:38:09 PM IST, down Rs 48.85 or 8.76% from the previous close of Rs 557.55. The company is a Small Cap with a market capitalisation of Rs 1,101.13 crore, and the latest Univest figures place it in the Pharmaceuticals & Drugs industry of the Healthcare sector.
The Lincoln Pharma share price fall is confirmed by the price data: the stock touched a low of Rs 507.90 during the day, and the latest price is only Rs 0.80 above it. Readers following Lincoln Pharma Stock Analysis will find the key figures below, including a P/E ratio of 11.58, a P/B ratio of 1.41, a return on equity of 12.30% and a return on capital employed of 16.27%.
Lincoln Pharmaceuticals (LINCOLN) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 508.7 |
| Previous Close | Rs 557.55 |
| Today's Move | -Rs 48.85 (-8.76%) |
| Open | Rs 560.3 |
| High | Rs 560.3 |
| Low | Rs 507.9 |
| Market Capitalisation | Rs 1,101.13 crore |
| Market Cap Category | Small Cap |
Lincoln Pharma Share Price Today shows a sharp one-day decline. Lincoln Pharmaceuticals is at Rs 508.70 against a previous close of Rs 557.55, a fall of Rs 48.85 or 8.76%, and the Small Cap stock now carries a market capitalisation of Rs 1,101.13 crore.
The day began with the stock opening at Rs 560.30, which is Rs 2.75 above the previous close. That open also stands as the day's high, so the Lincoln Pharma share price has not traded above Rs 560.30 today. The intraday low is Rs 507.90, and the stock is at Rs 508.70, which is Rs 51.60 below the open and Rs 0.80 above the low.
The full day range from Rs 560.30 down to Rs 507.90 spans Rs 52.40. Within that range, the latest price sits at the very bottom, a fact that frames the Lincoln Pharma Share Price Fall without adding any claim about market participants.
This is a single-day move rather than a multi-day slide. The decline is confined to the latest session, so the cumulative fall from the starting base price of Rs 557.55 is the same 8.76% seen today. With the price action established, a recent set of reported results is the next context to read.
Why Lincoln Pharmaceuticals (LINCOLN) May Be Moving Today
Lincoln Pharmaceuticals (LINCOLN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,101.13 crore |
| P/E Ratio | 11.58x |
| P/B Ratio | 1.41x |
| ROE | 12.3% |
| ROCE | 16.27% |
| EPS | Rs 48.15 |
| Book Value Per Share | Rs 396.34 |
| Dividend Yield | 0.32% |
Lincoln Pharmaceuticals (LINCOLN) fundamental metrics show P/E 11.58x, P/B 1.41x, ROE 12.3%, ROCE 16.27%. Taken on their own, these numbers offer context rather than a trading signal.
Lincoln Pharmaceuticals has a market capitalisation of Rs 1,101.13 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 11.58x, P/B at 1.41x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.3% and ROCE of 16.27%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 48.15, book value per share of Rs 396.34, dividend yield of 0.32%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.57x, median ROE of 11.23%, median ROCE of 13.1%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 11.58x |
| Benchmark Median P/E | 31.57x |
| Benchmark Average P/E | 46.23x |
| Benchmark P/E Range | 3.21x to 598.47x |
| Company P/B Ratio | 1.41x |
| Benchmark Median P/B | 2.75x |
| Benchmark Average P/B | 4.02x |
| Company ROE | 12.3% |
| Benchmark Median ROE | 11.23% |
| Benchmark Average ROE | 9.77% |
| Company ROCE | 16.27% |
| Benchmark Median ROCE | 13.1% |
| Benchmark Average ROCE | 12.73% |
| Company Market Capitalisation | Rs 1,101.13 crore |
| Benchmark Median Market Cap | Rs 715.8 crore |
| Benchmark Average Market Cap | Rs 13,817.44 crore |
Lincoln Pharmaceuticals (LINCOLN) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Lincoln Pharmaceuticals (LINCOLN) has a P/E ratio of 11.58x, which is below the benchmark median of 31.57x, a difference of -63.32%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Lincoln Pharmaceuticals (LINCOLN) has a ROE of 12.3%, which is above the benchmark median of 11.23%, a difference of +9.53%. Lincoln Pharmaceuticals (LINCOLN) has a ROCE of 16.27%, which is above the benchmark median of 13.1%, a difference of +24.2%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,22,282.95 | 34.87 | 4.88 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,51,611.12 | 86.78 | 14.37 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,75,182.22 | 81.67 | 9.44 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,16,408.7 | 25.9 | 4.34 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,15,616.01 | 107.97 | 20.94 | 18.31 | 18.2 |
Lincoln Pharmaceuticals (LINCOLN) has a P/E ratio of 11.58x compared with the displayed peer median of 81.67x. The comparison is relative and should not be read as a recommendation. Its ROE of 12.3% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 16.27% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Lincoln Pharmaceuticals (LINCOLN) has a market capitalisation of Rs 1,101.13 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Lincoln Pharma
- The price fall of 8.76% to Rs 508.70 from a previous close of Rs 557.55 is the headline move in today's price action.
- The intraday range from a high of Rs 560.30 to a low of Rs 507.90 shows where the Lincoln Pharma share price has traded today.
- A P/E of 11.58 is well below the industry median of 31.57, and the P/B of 1.41 is below the median of 2.75.
- Return on equity of 12.30% and return on capital employed of 16.27% are above the industry medians of 11.23% and 13.10%.
- A Small Cap market capitalisation of Rs 1,101.13 crore places the company in the Pharmaceuticals & Drugs industry group of 199 companies.
About Lincoln Pharma
Lincoln Pharmaceuticals is a listed company classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. It is a Small Cap, with a market capitalisation of Rs 1,101.13 crore at today's price of Rs 508.70. Companies in this industry earn money by developing, making and selling medicines, and the industry benchmark Univest uses covers 199 companies of widely different sizes.
Within that group, Lincoln Pharmaceuticals sits above the industry median market capitalisation of Rs 715.80 crore. Further company-level details are not part of the figures used here, so this overview stays with the sector and industry classification.
Track Lincoln Pharma Share Price on Univest
Use Lincoln Pharmaceuticals (LINCOLN) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Users can track the live Lincoln Pharma Share Price, fundamental ratios such as P/E, P/B, ROE and ROCE, 52-week levels and wider market insights for Lincoln Pharmaceuticals on Univest. The Univest stock page brings these figures together, so readers can follow the Lincoln Pharma Share Price Today and compare it with peers in the Pharmaceuticals & Drugs industry without searching across several sources.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
How much has Lincoln Pharma share price fallen today?
Ans. The Lincoln Pharma share price is at Rs 508.70, down Rs 48.85 or 8.76% from the previous close of Rs 557.55. The intraday low so far is Rs 507.90, and the stock is Rs 0.80 above it.
What is the Lincoln Pharma share price today?
Ans. Lincoln Pharmaceuticals is trading at Rs 508.70 as of 29 October 2026 at 12:38:09 PM IST. That is Rs 48.85 lower than the previous close of Rs 557.55, a decline of 8.76% on the day.
What are the day high and low for Lincoln Pharma share price?
Ans. The Lincoln Pharma share price opened at Rs 560.30, which is also the day high so far. The intraday low is Rs 507.90, and the stock is currently at Rs 508.70, so the day range is Rs 52.40.
What is the market capitalisation of Lincoln Pharma?
Ans. Lincoln Pharmaceuticals has a market capitalisation of Rs 1,101.13 crore and is classified as a Small Cap. The industry median market capitalisation for the Pharmaceuticals & Drugs group of 199 companies is Rs 715.80 crore.
What is the P/E ratio of Lincoln Pharma stock?
Ans. The P/E ratio of Lincoln Pharma is 11.58, with earnings per share of Rs 48.15. The industry median P/E is 31.57 and the average is 46.23, so the company sits well below both benchmark readings.
What are the ROE and ROCE of Lincoln Pharma?
Ans. Lincoln Pharma reports a return on equity of 12.30% and a return on capital employed of 16.27%. The industry medians are 11.23% for ROE and 13.10% for ROCE, so both company figures are above the medians.
What is the book value and P/B ratio of Lincoln Pharma?
Ans. The book value per share is Rs 396.34 and the P/B ratio is 1.41. The industry median P/B is 2.75 and the average is 4.02, so Lincoln Pharma is valued lower than the benchmark on this multiple.
What is the dividend yield of Lincoln Pharma?
Ans. Lincoln Pharma has a dividend yield of 0.32%. This is a historical and current ratio relating the payout to the share price of Rs 508.70, and it is not an assured future payout.
How does Lincoln Pharma compare with its Pharmaceuticals & Drugs peers?
Ans. Lincoln Pharma has a P/E of 11.58, lower than Sun Pharma, Divi's Laboratories, Torrent, Zydus and Laurus Labs. Its ROE of 12.30% and ROCE of 16.27% are also lower than each of those five peers.
Recent Articles

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026

Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





